Friday, September 30, 2022


Biotechnology News Magazine

ImmVira Reports Their Intravenous Administered oHSV MVR-T3011 IV Demonstrated Promising Clinical Biological Activities

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

ImmVira’s global first intravenous (“IV“) administered oncolytic herpes simplex virus (“oHSV“) product MVR-T3011 IV has completed the first three cohort escalation in the U.S. Phase I clinical trial, tested dosage from 1×106 to 1×108 PFU on 10 subjects with late-stage pancreatic, colon, lung, endometrial, breast, head and neck, gastrointestinal cancers and other advanced tumors. Preliminary biodistribution and clinical results of MVR-T3011 IV demonstrated promising biological activities of MVR-T3011 IV.

I. 80% of subjects’ blood samples have pre-existing Anti-Drug antibody (“ADA“) with herpes simplex virus-1 (“HSV-1“) IgG antibody positive at baseline. Post first and repeating dose of MVR-T3011, viral DNA can be detected in blood in a dose-dependent manner with additivity from repeating dose.

II. The numbers and percentages of various types of immune cells in peripheral blood of subjects were altered post MVR-T3011 dosing, and levels of cytokines IFNγ, IL-6, IL-8, and TNFα in blood samples were altered differentially. Some patients were observed with a significant increase in IFNγ on Day 3 post-dosing representing on-target biological activities.

III. In particular, one subject in the low-dose cohort (1×106 PFU) who had continuous 17-week Stable Disease (“SD“) was observed with a significant increase in IFNγ+ CD8 cells in peripheral blood, nearly doubled after administration. In addition, RNA sequence analysis in tumor biopsy on Day 50 post first dose showed that genes related to neutrophil activation, T-cell activation, adaptive immune response, leukocyte differentiation, and cytokine secretion were notably up-regulated compared to baseline.

Intravenous injection as a delivery method remains a huge scientific and clinical challenge for oHSV candidates for many years. In application, IV dosage tends to be higher compared to intratumoral injection so that a sufficient amount of virus can reach tumor sites, countered by a higher risk of systemic cytokine storm and other severe adverse events related to a higher dosage. Moreover, generic intravenous administered viruses may be neutralized by antibodies after repeating dose. ImmVira’s proprietary breakthrough viral candidate MVR-T3011 IV is designed to become the global first clinical-stage oHSV product via intravenous injection overcoming the aforementioned challenges. ImmVira will continue to monitor and analyze ongoing clinical biodistribution data in the human body as Phase I clinical study simultaneously goes on in the U.S. and China.


Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine